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Preexisting comorbidity adversely impacts breast cancer treatment and outcomes. We examined the incremental impact of
comorbidity undetected until cancer. We followed breast cancer patients in SEER-Medicare from 12 months before to 84 months
after diagnosis. Two comorbidity indices were constructed: the National Cancer Institute index, using 12 months of claims before
cancer, and a second index for previously undetected conditions, using three months after cancer. Conditions present in the first
were excluded from the second. Overall, 6,184 (10.1%) had ≥ 1 undetected comorbidity. Chronic obstructive pulmonary disease
(38%) was the most common undetected condition. In multivariable analyses that adjusted for comorbidity detected before cancer,
older age, later stage, higher grade, and poor performance status all were associatedwith higher odds of≥ 1 undetected comorbidity.
In stage I–III cancer, undetected comorbidity was associated with lower adjusted odds of receiving adjuvant chemotherapy (Odds
Ratio (OR) = 0.81, 95% Confidence Interval (CI) 0.73–0.90, 𝑃 < 0.0001; OR = 0.38, 95% CI 0.30–0.49, 𝑃 < 0.0001; index score
1 or ≥ 2, respectively), and with increased mortality (Hazard Ratio (HR) = 1.45, 95% CI 1.38–1.53, 𝑃 < 0.0001; HR = 2.38, 95%
CI 2.18–2.60, 𝑃 < 0.0001; index score 1 or ≥ 2). Undetected comorbidity is associated with less aggressive treatment and higher
mortality in breast cancer.
1. Introduction
Comorbidity adversely impacts the treatment [1–7] and
outcomes [1, 3, 6, 8–22] of breast cancer, especially in older
patients. For instance, studies have shown that breast cancer
patients with previously identified comorbidity are less likely
to receive adjuvant chemotherapy [2, 4, 5] and have higher
mortality [8]. Many such studies from the United States are
based on the Surveillance, Epidemiology, and End Results
cancer registry linked to health insurance claims (SEER-
Medicare) [1, 2, 5, 6, 17–20], where a common approach is
first to identify conditions appearing in claims prior to cancer
and then to use these conditions to construct a National
Cancer Institute (NCI) Comorbidity Index [23], which is an
adaptation of the Charlson index (CCI) [24].
Most studies based on SEER-Medicare include some
measures of comorbidity, and in a random sample of all
SEER-Medicare studies published between 2006 and 2011,
23/30 (77%) included the NCI Comorbidity Index. One
important limitation of this index, however, is that it ignores
conditions that are undetected in claims until after cancer
is diagnosed. Recently, we examined the incidence of unde-
tected comorbidity in breast cancer [25] and found that many
chronic conditions included in the NCI Comorbidity Index,
such as chronic obstructive pulmonary disease (COPD),
congestive heart failure (CHF), diabetes, and cerebrovascular
disease (CVD), remained undetected in claims until 1–3
months after cancer.
Undetected comorbidity could have additional implica-
tions for breast cancer treatment and outcomes.Therefore, in
this study we sought to describe risk factors for comorbidity
that remained undetected until breast cancer, and to assess
the added impact of undetected comorbidity on breast cancer
treatment and outcomes.
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2. Methods
2.1. Data. Presently SEER-Medicare [26] includes all
Medicare-eligible persons from 16 of the 17 SEER registries
through 2005 and theirMedicare claims for Part A (inpatient)
and Part B (outpatient and physician services) through 2007.
2.2. Patients. Patients were included if they were diagnosed
with breast cancer between 2001-01-01 and 2005-12-31, had
only one primary cancer diagnosed, and had at least 12
months of Medicare Part A and Part B coverage prior to can-
cer.Theywere excluded for the following reasons: male breast
cancer, cancer diagnosed before age 65, diagnosis made by
death certificate or autopsy, death within the first month fol-
lowing diagnosis, orMedicare enrollment less than 12months
before diagnosis. Patients were followed up from 12 months
before cancer until the end of the claims period (2007-
12-31) or death, whichever came first. Since SEER reports
only themonth of cancer diagnosis, the first day of thatmonth
was assigned as the date of diagnosis.
2.2.1. Variables. Patients were described according to their
demographic, clinical, and socioeconomic characteristics
[26, 27]. SEER does not include measures of performance
status, such as EasternCooperativeOncologyGroup. Instead,
we used Medicare claims to identify several indictors of poor
performance status, including the use of oxygen and related
respiratory therapy supplies, wheelchair and supplies, home
health agency services, and skilled nursing facility admis-
sions, all from 12 months before until 30 days after breast
cancer diagnosis [28].
The SEER-Medicare dataset contains information from
the 2000 US Census, reported at the tract level in which
the patient lives, for the percent of the population living in
poverty and the percent of those aged ≥25 years with some
college. We used these as indicators of the socioeconomic
status of individual patients in the cohort.
2.2.2. Comorbidity. Weconstructed two indices of comorbid-
ity. In SEER-Medicare, the gold standard for documenting the
presence of comorbidity prior to cancer is the NCI Comor-
bidity Index [23], which is usually constructed based on
claims from 12months to onemonth before cancer diagnosis.
Diagnosis and procedure codes are used to identify the 15
noncancer comorbidities in the CCI [24]. A weight is then
assigned to each condition, and the weights are summed to
obtain the index score for each patient. We followed this
approach to capture comorbidity detected prior to cancer and
classified patients as having a score =0, 1, or ≥2.
We applied the same algorithms used in the NCI
Comorbidity Index to construct an index of undetected
comorbidity, which was based on claims from the month of
cancer diagnosis up to two months after. For each patient,
conditions identified prior to cancer were excluded from the
undetected comorbidity index. If chemotherapy or radiation
began within three months following cancer diagnosis, the
observation period for the undetected comorbidity index was
truncated at that time to minimize the risk of misclassifying
treatment-related adverse events as undetected conditions.
As above, patientswere classified as having a score =0, 1, or≥2.
Since the minimum weight assigned to any condition in
either index is one (1), for clarity the term “≥ 1 condition/
comorbidity” is used in the Results to describe patients with
a score on either the previously detected or undetected
comorbidity index of ≥1.
2.2.3. Adjuvant Chemotherapy. Adjuvant chemotherapy was
identified based on Healthcare Common Procedure Coding
(HCPCS) “J” codes as recommended by the NCI [29]. The
first claim for chemotherapy had to appear within 180 days
of cancer diagnosis for the patient to be classified as having
received chemotherapy.
2.3. Mortality. The date of death was assigned by using the
Medicare date if available. When the Medicare date was
missing but the SEER date was available, the SEER date was
used. All other patients were assumed to be alive at the end
of the observation period.The cause of death was classified as
cancer or other cause.
2.4. Statistical Analysis. Multivariable analyses were per-
formed to examine risk factors for undetected comorbidity,
as well as associations between undetected comorbidity, adju-
vant chemotherapy, andmortality. Both indices of comorbid-
ity were included in analyses of treatment and mortality to
assess the incremental impact of undetected comorbidity.The
multivariable analysis of adjuvant chemotherapy was limited
to those with stage I–III disease [5]. All multivariable survival
analyses included only those who survived at least 3 months
after cancer diagnosis. Final models were selected through a
process of forward, stepwise regression, taking into account
statistical significance, interactions among covariables, and
whether a nonstatistically significant findingwas informative.
In almost all instances, at least one level of each variable
included in the final model was statistically significantly
different from the reference category of that variable. In
all instances, prior comorbidity and previously undetected
comorbidity were included in the final multivariable model.
However, we compared the magnitude and significance of
the coefficients on the previously undetected comorbidity in
models that included versus excluded prior comorbidity as a
covariable to assess the level of colinearity between these two.
3. Results
There were 61,002 patients in the final cohort, of whom 6,184
(10%) had ≥1 undetected comorbidity. The mean (standard
deviation) age was 76.0 (6.8), 54.6% were aged >75 years, 61%
were diagnosed with in situ or stage I disease, 14% had ≥1
indicator of poor performance, and 33% had ≥1 comorbidity
detected prior to cancer (Table 1). Those with ≥1 undetected
comorbidity also were more likely to have ≥1 condition
detected prior to cancer.
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Table 1: Patient characteristics.
Index of undetected comorbidity
Overall Score
(𝑛 = 61,002) 0 ≥1 𝑃 value
𝑛 % (𝑛 = 54,818) (𝑛 = 6,184)
𝑛 % 𝑛 %
Age at cancer diagnosis (years)
66–70 12,361 20.3 11,412 20.8 949 15.4
<0.000171–75 15,368 25.2 14,036 25.6 1,332 21.5
76–80 15,108 24.8 13,576 24.8 1,532 24.8
>80 18,165 29.8 15,794 28.8 2,371 38.3
Race/ethnicity
White 52,270 85.7 47,048 85.8 5,222 84.4
<0.0001Black 4,188 6.9 3,639 6.6 549 8.9
Hispanic 2,249 3.7 2,016 3.7 233 3.8
Other 2,295 3.8 2,115 3.9 180 2.9
Year of cancer diagnosis
2001 12,660 20.8 11,322 20.7 1,338 21.6
0.12
2002 12,452 20.4 11,166 20.4 1,286 20.8
2003 12,086 19.8 10,845 19.8 1,241 20.1
2004 11,929 19.6 10,765 19.6 1164 18.8
2005 11,875 19.5 10,720 19.6 1155 18.7
Index of prior comorbidity score (NCI Comorbidity Index)
0 41,001 67.2 37,365 68.2 3,636 58.8
<0.00011 13,480 22.1 11,952 21.8 1,528 24.7
≥2 6,521 10.7 5,501 10.0 1020 16.5
Stage at diagnosis
𝐼𝑛 𝑠𝑖𝑡𝑢 10,167 16.7 9,618 17.6 549 8.8
<0.0001
I 26,754 43.9 24,578 44.8 2,176 35.1
II 17,165 28.1 15,080 27.5 2,085 33.7
III 4,096 6.7 3,428 6.3 668 10.8
IV 2,820 4.6 2,114 3.9 706 11.4
Estrogen (ER) and progesterone (PR) receptor status
ER and PR positive 31,419 51.5 28,347 51.7 3,072 49.7
<0.0001ER or PR positive 8,081 13.3 7,203 13.1 878 14.2
ER and PR negative 7,165 11.8 6,353 11.6 812 13.1
Unknown/missing 14,337 23.5 12,915 23.6 1,422 23.0
Histological grade
1 12,419 20.4 11,403 20.8 1,016 16.4
<0.0001
2 23,407 38.4 21,090 38.5 2,317 37.5
3 15,291 25.1 13,528 24.7 1,763 28.5
4 1,881 3.1 1,710 3.1 171 2.8
Missing/unknown 8,004 13.1 7,087 12.9 917 14.8
Indicators of poor performance
0 52,460 86.0 47,599 86.8 4,861 78.6
<0.0001
≥1 8,542 14.0 7,219 13.2 1,323 21.4
Percent in census tract with some college
<25% 21,117 34.6 18,822 34.4 2,295 37.1
<0.0001
≥25% 39,885 65.4 35,996 65.7 3,889 62.9
Percent in census tract living in poverty
<5% 19,951 32.7 18,276 33.3 1,675 27.1
<0.00015–7% 8,718 14.3 7,919 14.5 799 12.9
8–12% 13,566 22.2 12,177 22.2 1,389 22.5
>12% 18,767 30.8 16,446 30.0 2,321 37.5
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Table 1: Continued.
Index of undetected comorbidity
Overall Score
(𝑛 = 61,002) 0 ≥1 𝑃 value
𝑛 % (𝑛 = 54,818) (𝑛 = 6,184)
𝑛 % 𝑛 %
Type of geographic area
Large metropolitan 34,481 56.5 31,090 56.7 3,391 54.8
<0.0001Metropolitan 17,568 28.8 15,840 28.9 1,728 27.9
Urban 3,674 6.0 3,242 5.9 432 7.0
Less urban/rural 5,279 8.7 4,646 8.5 633 10.2
3.1. Undetected Comorbidity. Among the 6,184 patients with
≥1 undetected comorbidity, there were a total of 7,593 condi-
tions. The most common were COPD (33% [2,023/6,184] of
patients), CHF (18%), diabetes (18% without complications;
4% with complications), myocardial infarction (14%), and
CVD (10%). In multivariable logistic regression, factors asso-
ciated with having ≥1 undetected condition were older age,
≥1 comorbidity detected prior to cancer, ≥1 indicator of poor
performance status, advanced stage, histological grade, living
in a census tract with more poverty, and living in an urban
area. Other race/ethnicity (compared to white) and later year
of cancer diagnosis were associated with lower odds of having
≥1 undetected condition (Table 2).
3.2. Chemotherapy. In multivariable analysis, undetected
comorbidity was associated with lower adjusted odds of
receiving adjuvant chemotherapy (Odds Ratio (OR) = 0.81,
95% Confidence Interval (CI) 0.73–0.90, 𝑃 < 0.0001; OR =
0.38, 95% CI 0.30–0.49, 𝑃 < 0.0001, for undetected comor-
bidity index score 1 or ≥2, resp.) (Table 3). Other factors
associated with lower odds were older age, later year of diag-
nosis, having ≥2 conditions detected prior to cancer, being
either estrogen and/or progesterone receptor positive, and
living in a census tract with >12% poverty. Factors associated
with higher odds included advanced stage and higher grade.
3.3. Survival. Overall, there were 13,208 (22% of cohort)
deaths: 5,191 (39% of all deaths) due to cancer; 5,823 (44%)
due to other causes; and (17%) unspecified. Among those
with ≥1 undetected comorbidity, 42% (2,575) died during the
observation period compared to 19% (10,633) of thosewith no
undetected conditions, and the unadjustedmortality rate was
significantly higher (𝑃 < 0.0001) (Figure 1).
In multivariable survival analysis, having undetected
comorbidity was associated with increased all-cause mortal-
ity (Hazard Ratio (HR) = 1.45, 95% CI 1.38–1.53, 𝑃 < 0.0001;
HR = 2.38, 95% CI 2.18–2.60, 𝑃 < 0.0001, for undetected
comorbidity index score 1 or ≥2, resp.), cancer mortality (HR
= 1.32 and HR = 1.67 for score 1 or ≥2), and other-cause
mortality (HR= 1.58 andHR=3.31 for score 1 or≥2) (Table 4).
In most instances, coefficients for undetected comorbidity
were comparable to or larger than those for comorbidity
detected prior to cancer.
3.4. Models with versus without Previously Detected Comor-
bidity. There was little difference in the magnitude and
significance of the coefficients for the previously undetected
comorbidity for multivariable models that included versus
excluded prior comorbidity as a covariable. For instance, the
coefficients for the chemotherapy model were 0.80 and 0.37
for undetected comorbidity scores of 1 and ≥2, respectively,
in the model that excluded prior comorbidity compared to
0.81 and 0.38 in the model that included prior comorbidity
(Table 3).
4. Discussion
We conducted an observational cohort study using SEER-
Medicare to describe risk factors for comorbidity that
remained undetected until breast cancer and to assess the
added impact of undetected comorbidity on breast cancer
treatment and outcomes. Advanced age, later stage diagnosis,
poor performance status, presence of comorbidity identified
prior to cancer, and poverty all were associatedwith increased
risk of undetected comorbidity. The strong monotonic asso-
ciation with cancer stage, as well as the association with
poverty, suggests the existence of shared risk factors, such
as poor health system contact prior to cancer diagnosis, [30,
31] resulting in delayed detection of both cancer and other
underlying chronic conditions including COPD, CHF, and
diabetes. One important implication of our study is that those
with other established risk factors for poor outcomes in breast
cancer, including advanced age, later stage, and poor per-
formance status, also are at greatest risk for undetected
comorbidity.
Patients with undetected comorbidity were less likely to
receive adjuvant chemotherapy. Furthermore, the effect sizes
were larger for undetected comorbidity than for comorbidity
detected prior to cancer. For example the Odds Ratio for an
undetected comorbidity index score ≥2 was 0.38 compared
to 0.74 for a score ≥2 on the index of conditions prior to
cancer. Since identification of conditions was based on claims
for medical services, one hypothesis is that undetected con-
ditions were more severe because they had not been treated.
Others have speculated that one way comorbidity can influ-
ence treatment and outcomes in cancer is by distracting the
healthcare team from the appropriate management of both
International Journal of Breast Cancer 5
Table 2: Risk of undetected comorbidity.
OR 95% CI 𝑃 value
Lower Upper
Age at cancer diagnosis (years)
66–70 Reference category
71–75 1.12 1.02 1.22 0.02
76–80 1.28 1.17 1.39 <0.0001
>80 1.53 1.41 1.66 <0.0001
Race/ethnicity
White Reference category
Black 1.04 0.94 1.16 0.41
Hispanic 0.94 0.81 1.08 0.39
Other 0.83 0.71 0.97 0.02
Year of cancer diagnosis
2001 Reference category
2002 0.99 0.91 1.07 0.75
2003 0.98 0.90 1.07 0.68
2004 0.93 0.85 1.01 0.08
2005 0.92 0.84 1.00 0.05
Index of prior comorbidity score (NCI Comorbidity Index)
0 Reference category
1 1.20 1.13 1.28 <0.0001
≥2 1.50 1.38 1.63 <0.0001
Indicators of poor performance
0 Reference category
≥1 1.30 1.21 1.40 <0.0001
Stage at diagnosis
𝐼𝑛 𝑠𝑖𝑡𝑢 Reference category
I 1.66 1.49 1.85 <0.0001
II 2.40 2.15 2.67 <0.0001
III 3.26 2.87 3.71 <0.0001
IV 5.51 4.85 6.26 <0.0001
Histological grade
Well differentiated Reference category
Moderately differentiated 1.11 1.02 1.20 0.01
Poorly differentiated 1.15 1.05 1.26 <0.01
Undifferentiated/anaplastic 1.25 1.05 1.50 0.01
Missing/unknown 1.14 1.03 1.27 0.01
Estrogen (ER) and progesterone (PR) receptor status
ER and PR negative Reference category
ER or PR positive 1.05 0.94 1.16 0.39
ER and PR positive 1.00 0.92 1.09 1.00
Unknown/missing 1.14 1.03 1.27 0.01
Percent in census tract with some college
<25% Reference category
≥25% 0.99 0.93 1.05 0.70
Percent in census tract living in poverty
<5% Reference category
5–7% 1.07 0.98 1.17 0.12
8–12% 1.17 1.08 1.27 <0.0001
>12% 1.34 1.25 1.45 <0.0001
Type of geographic area
Large metropolitan Reference category
Metropolitan 0.97 0.91 1.04 0.42
Urban 1.14 1.02 1.28 0.02
Less urban/rural 1.09 0.99 1.20 0.08
OR: Odds Ratio; CI: Confidence Interval.
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Table 3: Adjuvant chemotherapy.
OR 95% CI 𝑃 value
Lower Upper
Age at cancer diagnosis (years)
66–70 Reference category
71–75 0.55 0.51 0.59 <0.0001
76–80 0.25 0.23 0.27 <0.0001
>80 0.05 0.04 0.05 <0.0001
Race/ethnicity
White Reference category
Black 0.94 0.84 1.05 0.27
Hispanic 1.15 0.99 1.32 0.06
Other 1.13 0.98 1.31 0.10
Year of cancer diagnosis
2001 Reference category
2002 0.95 0.87 1.04 0.26
2003 0.86 0.79 0.94 <0.001
2004 0.88 0.80 0.96 <0.01
2005 0.79 0.72 0.86 <0.0001
Index of prior comorbidity score (NCI Comorbidity Index)
0 Reference category
1 0.96 0.90 1.03 0.28
≥2 0.74 0.66 0.82 <0.0001
Index of undetected comorbidity score
0 Reference category
1 0.81 0.73 0.90 <0.0001
≥2 0.38 0.30 0.49 <0.0001
Indicators of poor performance
0 Reference category
≥1 0.56 0.51 0.62 <0.0001
Stage at diagnosis
I Reference category
II 8.73 8.17 9.34 <0.0001
III 21.87 19.83 24.12 <0.0001
Histological grade
Well differentiated Reference category
Moderately differentiated 1.58 1.44 1.72 <0.0001
Poorly differentiated 2.54 2.31 2.79 <0.0001
Undifferentiated/anaplastic 2.01 1.60 2.53 <0.0001
Missing/unknown 1.51 1.33 1.71 <0.0001
Estrogen (ER) and progesterone (PR) receptor status
ER and PR negative Reference category
Either ER or PR positive 0.32 0.29 0.35 <0.0001
Both ER and PR positive 0.24 0.22 0.26 <0.0001
Unknown/missing 0.30 0.27 0.34 <0.0001
Percent in census tract with some college
<25% Reference category
≥25% 1.02 0.95 1.08 0.65
Percent in census tract living in poverty
<5% Reference category
5–7% 0.93 0.85 1.02 0.13
8–12% 0.93 0.86 1.01 0.08
>12% 0.91 0.84 0.98 0.01
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Table 3: Continued.
OR 95% CI 𝑃 value
Lower Upper
Type of geographic area
Large metropolitan Reference category
Metropolitan 1.12 1.05 1.20 <0.01
Urban 1.14 1.01 1.29 0.03
Less urban/rural 1.06 0.95 1.18 0.32
OR: Odds Ratio; CI: Confidence Interval.
0.00
0.25
0.50
0.75
1.00
0 20 40 60 80
Months to death following breast cancer diagnosis
No postdiagnosis comorbidities
At least 1 postdiagnosis comorbidity 
P
Log-rank test: 
𝜒2 = 1491.83
(P value < 0.0001)
NA: not applicable
Months following breast cancer diagnosis.
Index of undetected comorbidity score = 0
Number at risk
Number at risk
Number of deaths in interval
Number of deaths in interval
Index of undetected comorbidity score ≥ 1
0 20 40 60 80
53,792 47,266 29,287 13,590 1,129
4,086 3,378 2,035 676 NA
1,154 667 307 94 NA
5,805 4,365 2,463 1,058 84
Figure 1: Unadjusted Survival.
[32] cancer and other conditions. The fact that effect sizes
were larger for undetected conditions suggest that these may
pose greater challenges for the healthcare team than those
that have a history of being treated prior to cancer.
Undetected comorbidity also was associated with
increased overall cancer and other-cause mortality. The
impact on other-cause mortality was larger than on cancer
mortality. However, all six HRs in the three survival
analyses were highly statistically significant, and, in general,
HRs for undetected comorbidity were larger than those for
comorbidity detected prior to cancer. Again, this supports the
hypothesis that undetected comorbidity may be more severe
and that it may pose greater challenges to the healthcare team
than conditions appearing in claims and, by implication,
treated prior to cancer.
It is likely that the impact of undetected comorbidity on
cancer mortality is partially explained by its direct impact
on the likelihood of receiving adjuvant chemotherapy. The
link between adjuvant chemotherapy and survival in breast
cancer is well established, and adjuvant chemotherapy was
not included in our survival analyses to avoid over adjustment
of the models.
Our study has several limitations. First, as discussed
above, we cannot rule out the possibility that unobserved
factors may have confounded observed associations between
the presence of undetected comorbidity and several of the
observed risk factors, notably cancer stage at diagnosis.
Second, both comorbidity indices in our study are based
on claims and consequently have less-than-perfect sensitivity
and specificity for the conditions of interest. Therefore,
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conditions that simply were not found in claims prior to
cancer due to limitations of the algorithms in the NCI
Comorbidity Index, butwhich actually had been detected and
possibly treated at an earlier date,may have beenmisclassified
as undetected.Third, since SEER includes only themonth and
not the day of cancer diagnosis, we elected to assign the first
day of the month as the date of cancer diagnosis. Had we
elected to assign the last day of the month, all conditions
classified as previously undetected by virtue of first appearing
in themonth of cancer diagnosis would have been reclassified
as previously detected.
5. Conclusions
Limitations notwithstanding, our findings indicate that those
patients with established risk factors for poor outcomes in
breast cancer, including advanced age, later stage, and poor
performance status, also are at greatest risk for undetected
comorbidity. Furthermore, undetected comorbidity appears
to confer greater additional risk of poor outcomes than
comorbidity detected prior to cancer, suggesting that it may
be more severe and that it may pose additional challenges to
the healthcare team. However, these hypotheses would
require further investigation.
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